Enlivex Therapeutics (ENLV) Competitors $1.05 0.00 (0.00%) As of 11:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENLV vs. COYA, MGNX, TCRX, SRZN, ORMP, PLRX, ANEB, IPA, ANIX, and VIRIShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Coya Therapeutics (COYA), MacroGenics (MGNX), TScan Therapeutics (TCRX), Surrozen (SRZN), Oramed Pharmaceuticals (ORMP), Pliant Therapeutics (PLRX), Anebulo Pharmaceuticals (ANEB), ImmunoPrecise Antibodies (IPA), Anixa Biosciences (ANIX), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. Its Competitors Coya Therapeutics MacroGenics TScan Therapeutics Surrozen Oramed Pharmaceuticals Pliant Therapeutics Anebulo Pharmaceuticals ImmunoPrecise Antibodies Anixa Biosciences Virios Therapeutics Coya Therapeutics (NASDAQ:COYA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation. Which has better valuation and earnings, COYA or ENLV? Coya Therapeutics has higher revenue and earnings than Enlivex Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$3.55M26.77-$14.88M-$1.24-4.58Enlivex TherapeuticsN/AN/A-$15.01M-$0.58-1.81 Do analysts rate COYA or ENLV? Coya Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 190.44%. Enlivex Therapeutics has a consensus price target of $10.00, indicating a potential upside of 852.38%. Given Enlivex Therapeutics' higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Coya Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, COYA or ENLV? Coya Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Is COYA or ENLV more profitable? Enlivex Therapeutics' return on equity of -58.31% beat Coya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -61.05% -53.61% Enlivex Therapeutics N/A -58.31%-50.32% Do institutionals and insiders believe in COYA or ENLV? 39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer COYA or ENLV? In the previous week, Coya Therapeutics had 5 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 8 mentions for Coya Therapeutics and 3 mentions for Enlivex Therapeutics. Coya Therapeutics' average media sentiment score of 0.19 beat Enlivex Therapeutics' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryEnlivex Therapeutics beats Coya Therapeutics on 7 of the 13 factors compared between the two stocks. Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.83M$2.56B$5.78B$10.38BDividend YieldN/A57.29%5.74%4.64%P/E Ratio-1.8123.0977.0826.78Price / SalesN/A546.30507.10167.11Price / CashN/A169.7137.1760.63Price / Book1.055.3713.696.40Net Income-$15.01M$32.95M$3.29B$271.62M7 Day Performance-1.87%1.61%3.23%3.33%1 Month PerformanceN/A7.76%8.37%10.15%1 Year Performance-30.00%-2.89%82.31%31.19% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics1.9721 of 5 stars$1.05flat$10.00+852.4%-32.3%$24.83MN/A-1.8170COYACoya Therapeutics2.7792 of 5 stars$5.68-6.1%$16.50+190.5%-5.3%$101.19M$3.55M-4.586Analyst ForecastMGNXMacroGenics4.4845 of 5 stars$1.56-1.9%$3.60+130.8%-47.6%$100.50M$149.96M-2.74430News CoverageAnalyst UpgradeTCRXTScan Therapeutics2.6412 of 5 stars$1.69-4.0%$7.80+361.5%-69.0%$99.88M$2.82M-1.55100Positive NewsSRZNSurrozen2.1407 of 5 stars$11.65+0.7%$38.50+230.5%+49.6%$99.12M$10.65M-0.8180ORMPOramed Pharmaceuticals0.3348 of 5 stars$2.32-3.7%N/A+0.8%$98.82M$2M-6.6310PLRXPliant Therapeutics4.1448 of 5 stars$1.53-3.8%$8.19+435.1%-88.1%$97.61M$1.58M-0.4590Positive NewsANEBAnebulo Pharmaceuticals1.6627 of 5 stars$2.46+3.8%$5.50+123.6%+23.5%$97.37MN/A-9.464Upcoming EarningsIPAImmunoPrecise Antibodies2.5842 of 5 stars$2.10+8.5%$4.00+90.9%+217.4%$96.68M$17.59M-3.0880Gap UpANIXAnixa Biosciences3.3446 of 5 stars$3.52+20.1%$9.00+155.7%-2.3%$96.61MN/A-10.065High Trading VolumeVIRIVirios TherapeuticsN/A$4.89-0.1%$5.00+2.2%+2,350.0%$94.17MN/A-18.115Gap Up Related Companies and Tools Related Companies COYA Competitors MGNX Competitors TCRX Competitors SRZN Competitors ORMP Competitors PLRX Competitors ANEB Competitors IPA Competitors ANIX Competitors VIRI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENLV) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENLV Stock Alerts